PP
VRTX icon

PDS Planning’s Vertex Pharmaceuticals VRTX Stock Holding History

PDS Planning’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$673K Sell
1,354
-53
-4% -$23.5K 0.04% 237
2026
Q1 		$628K Buy
1,407
+90
+7% +$42K 0.04% 218
2025
Q4 		$597K Buy
1,317
+174
+15% +$75K 0.04% 220
2025
Q3 		$448K Sell
1,143
-100
-8% -$41.8K 0.03% 272
2025
Q2 		$553K Buy
1,243
+85
+7% +$39.2K 0.04% 218
2025
Q1 		$561K Buy
1,158
+334
+41% +$156K 0.05% 192
2024
Q4 		$332K Sell
824
-18
-2% -$8.34K 0.03% 269
2024
Q3 		$392K Buy
842
+27
+3% +$13K 0.04% 234
2024
Q2 		$382K Sell
815
-8
-1% -$3.47K 0.04% 218
2024
Q1 		$344K Buy
823
+46
+6% +$19.4K 0.04% 225
2023
Q4 		$316K Buy
777
+11
+1% +$4.06K 0.04% 226
2023
Q3 		$266K Buy
766
+11
+1% +$3.85K 0.03% 231
2023
Q2 		$266K Sell
755
-175
-19% -$59K 0.03% 239
2023
Q1 		$293K Buy
+930
New +$279K 0.04% 198

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

PDS Planning's VRTX Position: Q2 2026 in Review

PDS Planning reduced its Vertex Pharmaceuticals (VRTX) stake by 3.8% in Q2 2026, selling an estimated $23.5K and leaving 1,354 shares worth $673K. The position accounts for 0.04% of the portfolio, ranked #237.

PDS Planning first reported a position in VRTX in Q1 2023 and has held it in 14 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • PDS Planning held 1,354 shares of Vertex Pharmaceuticals worth $673K as of Q2 2026.
  • PDS Planning sold 53 Vertex Pharmaceuticals shares in Q2 2026, an estimated $23.5K.
  • Vertex Pharmaceuticals made up 0.04% of PDS Planning's portfolio in Q2 2026, its #237 holding.
  • PDS Planning first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on PDS Planning's 13F filing for Q2 2026, filed 5 Aug 2026.